UBS downgraded GE HealthCare (GEHC) to Sell from Neutral with a price target of $77, up from $73. The firm says the “enthusiasm” around Flyrcado and photon-counting computed tomography, which has driven GE HealthCare shares to near all-time highs, is understandable. However, the analyst now sees risks, saying the company’s “best-case execution scenarios” are priced into the stock. The positives are well known, but the risks less so, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- GE HealthCare price target raised to $98 from $86 at Goldman Sachs
- GE HealthCare price target raised to $95 from $90 at Stifel
- GE HealthCare urges shareholders to reject ‘mini-tender’ offer by Potemkin
- Midday Fly By: Nvidia launches Rubin platform, Vistra to acquire Cogentrix
- NXP Semiconductors, GE HealthCare collaborate for AI in acute care